Lung cancer is one of the most common cancers worldwide, accounting for more than 2 million new cases diagnosed each year1. There are 2 main types of lung cancer—small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)2. NSCLC accounts for approximately 85% of lung cancer diagnoses3.

More people die of lung cancer every year than from any other cancer4. Currently, the five-year survival rate for lung cancer remains at about 20%, decreasing further when the disease is diagnosed at later stages5.

Novartis is committed to working with the scientific and medical communities to reimagine the treatment of lung cancer and pursue advances in medicine that could potentially extend the survival of people living with lung cancer.

A patient asking a doctor about a clinical trial

Sound Up for Lung Cancer

Empowering lung cancer patients to speak up and have open conversations with their doctors.

References:

  1. World Health Organization. Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed August 9, 2022.
  2. Lemjabbar-Alaoui H, Hassan O, Yang UW, et al. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015;1856(2):189-210.
  3. American Cancer Society. About Lung Cancer. Available at https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed August 9, 2022.
  4. Siegel, RL, Miller, KD, Fuchs, H, Jemal, A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71: 7-33. https://doi.org/10.3322/caac.21654.
  5. American Cancer Society. Lung Cancer Survival Rates. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed August 9, 2022.